APVO · Aptevo Therapeutics Inc.
$1.80
+0.04 (+2.27%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“When considered in aggregate, these factors raise substantial doubt about our ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$3.39M
Shares
1.80M
Volume · Oct 5
28.05K
Avg daily vol (3M)
111.65K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.76
Open$1.80
Day$1.76–1.80
52W close$1.71–31.68
Avg vol 30d156K
Short int188K · 10.4% float · 1.0d
Short vol32%
DataMar 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$12.98M
Trailing 12 months
Net income (TTM)
−$26.41M
Trailing 12 months
Revenue growth YoY
+28.6%
Year over year
Operating margin
-919.7%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 92,847.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,817.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
10.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−68%
below
Price vs 50-day avg
−35%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−63%
trailing
YTD return
−81%
this year
Relative strength
−75%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.43% of float · ▲ +59.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−75%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-25.6M
Balance sheet
$19.2M
net cash
Quant / Vol
risk profile
Volatility
95%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−68%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.43% of float · ▲ +59.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 0%
Range high $32
vs 200-day avg -68%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APVO
this stock
Aptevo Therapeutics Inc.
|
$3.39M | -81.3% | -74.7% | — | 10.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APVO | -6.9% | +2.9% | -62.9% | -3.3% | -81.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -6.7% | +3.4% | -75.1% | -4.2% | -94.2% |